Blood eosinophil subtype distribution following treatment with mepolizumab in patients with severe eosinophilic asthma - Vienna 2024

Unravelling the potential of interleukin-5 pathways in asthma

Chair(s): Francisco Javier Salgado Castro, Madeleine R?dinger

Session type: Poster session

Blood eosinophil subtype distribution following treatment with mepolizumab in patients with severe eosinophilic asthma

Airidas Rimkunas

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Effect of dupilumab on small airway dysfunction in real-life severe asthma: Japanese multi-center prospective cohort

Toshihiro Shirai

Poster

Abstract

Exacerbation reduction data with benralizumab in subgroups of patients with severe eosinophilic asthma (SEA) from Central Europe and Baltics (BREEZE)

Kestutis Malakauskas

Poster

Abstract

Diagnostic value of blood inflammatory and oxidative stress markers in severe allergic eosinophilic asthma patients undergoing anti-IL-5 therapy

Andrius Januskevicius

Poster

Abstract

Reduction in FeNO on anti-IL5 biologics is associated with clinical remission of severe asthma

Marianne Baastrup Soendergaard

Poster

Abstract

Dupilumab Reduces Exacerbations and FeNO Levels and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Michael E. Wechsler

Poster

Abstract

Effect of benralizumab on airway mucus, air-trapping and airway volume, assessed by functional respiratory imaging in severe eosinophilic asthma

Lennart Conemans

Poster

Abstract

Effectiveness of Mepolizumab in patients with late-onset severe eosinophilic asthma and fixed obstruction, a 2-Year Follow-Up: The MESILICO study

Kalliopi Domvri

Poster

Abstract

Early and continued asthma control improvement in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab initiation: real-world XALOC-2 programme

Lieven Dupont

Poster

Abstract

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab

Arnaud Bourdin

Poster

Abstract

The influence of Adherence to inhaled Corticosteroids (ICS) on treatment Response to mepolizumab treatment in severe Eosinophilic asthma

Mohammed Almutairi

Poster

Abstract

Effect of immunosuppressant coadministration with mepolizumab for moderate to severe eosinophilic granulomatosis with polyangiitis(EGPA)

Naomi Tsurikisawa

Poster

Abstract

Baseline characteristics of patients with severe eosinophilic asthma treated with benralizumab who reduced to anti-inflammatory reliever only vs high-, medium- or low-dose inhaled corticosteroid/formoterol: SHAMAL post-hoc analysis

Brian Kent

Poster

Abstract

Impact of anti-eosinophilic biologic strategies on bronchial hyperreactivity in severe asthma

Mario Di Stasio

Poster

Abstract

Factors influencing lung function changes when inhaled corticosteroid/formoterol is reduced in patients with severe eosinophilic asthma treated with benralizumab

David Jackson

Poster

Abstract

Asthma Exacerbation Profile on open label treatment with Benralizumab for severe eosinophilic asthma [BenRex]

Jennifer Logan

Poster

Abstract

Clinical variables associated with achieving improvement in asthma control with mepolizumab in patients from the REDES study

Christian Domingo Ribas

Poster

Abstract

Blood eosinophil subtype distribution following treatment with mepolizumab in patients with severe eosinophilic asthma

Airidas Rimkunas

Poster

Abstract

Asthma loss of control after switch from anti-IL5/5R drugs to dupilumab in severe eosinophilic asthma: a case series.

Camille Taill

Poster

Abstract

Evaluation of mepolizumab (MPZ) treatment in Eosinophilic Granulomatosis with Polyangiitis (EGPA) patients in an asthma clinic

Laura Castellanos L?pez

Poster

Abstract

Late Breaking Abstract - Benralizumab reduces eosinophils and ANCA in sputum in EGPA

Manali Mukherjee

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}